The delicate balance of macrophages in colorectal cancer; their role in tumour development and therapeutic potential

Immunobiology

Volumn 222, Issue 1, 2017, Pages 21-30

  Braster, R ^a   Bogels M ^a   Beelen, R H J ^a   van Egmond, M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal cancer; Immune therapy; Macrophage activation; Macrophages; Monoclonal antibodies

Indexed keywords

CD68 ANTIGEN; CHEMOKINE RECEPTOR CCR2; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMCCS 4; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE DERIVED CHEMOKINE; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PAM 3CSK4; STAT3 PROTEIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VON WILLEBRAND FACTOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ANTIBODY DEPENDENT PHAGOCYTOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; CELL PLASTICITY; CELL POPULATION; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; METASTATIC COLORECTAL CANCER; NONHUMAN; NUCLEAR REPROGRAMMING; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ULCERATIVE COLITIS; WOUND HEALING; ANIMAL; CELL TRANSFORMATION; COLORECTAL TUMOR; COMPLICATION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; MACROPHAGE; MACROPHAGE ACTIVATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; INFLAMMATION; MACROPHAGE ACTIVATION; MACROPHAGES; MOLECULAR TARGETED THERAPY;

EID: 84940911278     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2015.08.011     Document Type: Review

References (129)

1. Al Murri, A.M., Wilson, C., Lannigan, A., Doughty, J.C., Angerson, W.J., McArdle, C.S., McMillan, D.C., Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br. J. Cancer 96 (2007), 891–895.
2. Allen, M., Louise, J.J., Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J. Pathol. 223 (2011), 162–176.
3. Bailey, C., Negus, R., Morris, A., Ziprin, P., Goldin, R., Allavena, P., Peck, D., Darzi, A., Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin. Exp. Metastasis 24 (2007), 121–130.
4. Bakema, J.E., van Egmond, M., Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer. Curr. Top. Microbiol. Immunol. 382 (2014), 373–392.
5. Balkwill, F.R., Mantovani, A., Cancer-related inflammation: common themes and therapeutic opportunities. Semin. Cancer Biol. 22 (2012), 33–40.
6. Bayne, L.J., Beatty, G.L., Jhala, N., Clark, C.E., Rhim, A.D., Stanger, B.Z., Vonderheide, R.H., Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21 (2012), 822–835.
7. Biswas, S.K., Mantovani, A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11 (2010), 889–896.
8. Bögels, M., Braster, R., Nijland, P.G., Gül, N., van, de, L.W., Fijneman, R.J., Meijer, G.A., Jimenez, C.R., Beelen, R.H., van, E., gmond, M., Carcinoma origin dictates differential skewing of monocyte function. Oncoimmunology 1 (2012), 798–809.
9. Boue, F., Pastran, Z., Spielmann, M., Le, C.T., Subirana, R., Sevin, D., Paoletti, C., Brandely, M., Avril, M.F., Sancho-Garnier, H., A phase I trial with recombinant interferon gamma (Roussel UCLAF) in advanced cancer patients. Cancer Immunol. Immunother. 32 (1990), 67–70.
10. Braster, R., O'Toole, T., van, E., gmond, M., Myeloid cells as effector cells for monoclonal antibody therapy of cancer. Methods 65 (2014), 28–37.
11. Brill, T.H., Kubler, H.R., Pohla, H., Buchner, A., Fend, F., Schuster, T., van Randenborgh, H., Paul, R., Kummer, T., Plank, C., Eisele, B., Breul, J., Hartung, R., Schendel, D.J., Gansbacher, B., Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. Hum. Gene Ther. 20 (2009), 1641–1651.
12. Bruley-Rosset, M., Florentin, I., Mathe, G., In vivo and in vitro macrophage activation by systemic adjuvants. Agents Actions 6 (1976), 251–255.
13. Casazza, A., Laoui, D., Wenes, M., Rizzolio, S., Bassani, N., Mambretti, M., Deschoemaeker, S., Van, G., inderachter, J.A., Tamagnone, L., Mazzone, M., Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 24 (2013), 695–709.
14. Cheung, I.Y., Hsu, K., Cheung, N.K., Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 30 (2012), 426–432.
15. Chitu, V., Stanley, E.R., Colony-stimulating factor-1 in immunity and inflammation. Curr. Opin. Immunol. 18 (2006), 39–48.
16. Chow, M.T., Moller, A., Smyth, M.J., Inflammation and immune surveillance in cancer. Semin. Cancer Biol. 22 (2012), 23–32.
17. Coussens, L.M., Zitvogel, L., Palucka, A.K., Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 339 (2013), 286–291.
18. Croce, C.M., Oncogenes and cancer. N. Engl. J. Med. 358 (2008), 502–511.
19. Cui, W.Y., Zhao, S., Polanowska-Grabowska, R., Wang, J., Wei, J., Dash, B., Chang, S.L., Saucerman, J.J., Gu, J., Li, M.D., Identification and characterization of poly(I:C)-induced molecular responses attenuated by nicotine in mouse macrophages. Mol. Pharmacol. 83 (2013), 61–72.
20. de Bono, J.S., Dalgleish, A.G., Carmichael, J., Diffley, J., Lofts, F.J., Fyffe, D., Ellard, S., Gordon, R.J., Brindley, C.J., Evans, T.R., Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin. Cancer Res. 6 (2000), 397–405.
21. Deng, L., Zhou, J.F., Sellers, R.S., Li, J.F., Nguyen, A.V., Wang, Y., Orlofsky, A., Liu, Q., Hume, D.A., Pollard, J.W., Augenlicht, L., Lin, E.Y., A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am. J. Pathol. 176 (2010), 952–967.
22. Dinney, C.P., Tanguay, S., Bucana, C.D., Eve, B.Y., Fidler, I.J., Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice. J. Interferon Cytokine Res. 15 (1995), 585–592.
23. Doedens, A.L., Stockmann, C., Rubinstein, M.P., Liao, D., Zhang, N., DeNardo, D.G., Coussens, L.M., Karin, M., Goldrath, A.W., Johnson, R.S., Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 70 (2010), 7465–7475.
24. Elnemr, A., Ohta, T., Yachie, A., Fushida, S., Ninomiya, I., Nishimura, G.I., Yamamoto, M., Ohkuma, S., Miwa, K., N-Ethylmaleimide-enhanced phosphatidylserine externalization of human pancreatic cancer cells and immediate phosphatidylserine-mediated phagocytosis by macrophages. Int. J. Oncol. 16 (2000), 1111–1116.
25. Engelhardt, R., Mackensen, A., Galanos, C., Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res. 51 (1991), 2524–2530.
26. Erreni, M., Mantovani, A., Allavena, P., Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron. 4 (2011), 141–154.
27. Farinha, P., Masoudi, H., Skinnider, B.F., Shumansky, K., Spinelli, J.J., Gill, K., Klasa, R., Voss, N., Connors, J.M., Gascoyne, R.D., Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106 (2005), 2169–2174.
28. Fidler, I.J., Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages. Cancer Res. 34 (1974), 1074–1078.
29. Forssell, J., Oberg, A., Henriksson, M.L., Stenling, R., Jung, A., Palmqvist, R., High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin. Cancer Res. 13 (2007), 1472–1479.
30. Fujimoto, J., Sakaguchi, H., Aoki, I., Tamaya, T., Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res. 60 (2000), 2632–2635.
31. Funada, Y., Noguchi, T., Kikuchi, R., Takeno, S., Uchida, Y., Gabbert, H.E., Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol. Rep. 10 (2003), 309–313.
32. Gabrilovich, D.I., Ostrand-Rosenberg, S., Bronte, V., Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12 (2012), 253–268.
33. Goede, V., Brogelli, L., Ziche, M., Augustin, H.G., Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int. J. Cancer 82 (1999), 765–770.
34. Gordon, S., Martinez, F.O., Alternative activation of macrophages: mechanism and functions. Immunity 32 (2010), 593–604.
35. Gratchev, A., Kzhyshkowska, J., Kothe, K., Muller-Molinet, I., Kannookadan, S., Utikal, J., Goerdt, S., Mphi1 and Mphi2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals. Immunobiology 211 (2006), 473–486.
36. Grivennikov, S.I., Inflammation and colorectal cancer: colitis-associated neoplasia. Semin. Immunopathol. 35 (2013), 229–244.
37. Grivennikov, S.I., Greten, F.R., Karin, M., Immunity, inflammation, and cancer. Cell 140 (2010), 883–899.
38. Groot, K.B., Rahbari, N.N., Buchler, M.W., Koch, M., Weitz, J., Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann. Surg. Oncol. 20 (2013), 2156–2165.
39. Guiducci, C., Vicari, A.P., Sangaletti, S., Trinchieri, G., Colombo, M.P., Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65 (2005), 3437–3446.
40. Gül, N., Babes, L., Kubes, P., van Egmond, M., Macrophages in the liver prevent metastasis by efficiently eliminating circulating tumor cells after monoclonal antibody immunotherapy. Oncoimmunology, 3, 2014, e28441.
41. Gül, N., Babes, L., Siegmund, K., Korthouwer, R., Bögels, M., Braster, R., Vidarsson, G., ten Hagen, T.L., Kubes, P., van Egmond, M., Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J. Clin. Invest. 124 (2014), 812–823.
42. Gül, N., Bögels, M., Grewal, S., van der Meer, A.J., Rojas, L.B., Fluitsma, D.M., van den Tol, M.P., Hoeben, K.A., van Marle, J., de Vries, H.E., Beelen, R.H., van Egmond, M., Surgery-induced reactive oxygen species enhance colon carcinoma cell binding by disrupting the liver endothelial cell lining. Gut 60 (2011), 1076–1086.
43. Gupta, R.B., Harpaz, N., Itzkowitz, S., Hossain, S., Matula, S., Kornbluth, A., Bodian, C., Ullman, T., Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133 (2007), 1099–1105.
44. Hamada, I., Kato, M., Yamasaki, T., Iwabuchi, K., Watanabe, T., Yamada, T., Itoyama, S., Ito, H., Okada, K., Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res. 22 (2002), 4281–4284.
45. Hanada, T., Nakagawa, M., Emoto, A., Nomura, T., Nasu, N., Nomura, Y., Prognostic value of tumor-associated macrophage count in human bladder cancer. Int. J. Urol. 7 (2000), 263–269.
46. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
47. Hao, N.B., Lu, M.H., Fan, Y.H., Cao, Y.L., Zhang, Z.R., Yang, S.M., Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol., 2012, 2012, 948098.
48. Hartveit, F., The role of the large peritoneal macrophage in tumour homograft rejection. Br. J. Cancer 18 (1964), 146–149.
49. Hasita, H., Komohara, Y., Okabe, H., Masuda, T., Ohnishi, K., Lei, X.F., Beppu, T., Baba, H., Takeya, M., Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 101:8 (2010), 1913–1919 August.
50. Hoedemakers, R.M., Vossebeld, P.J., Daemen, T., Scherphof, G.L., Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome-encapsulated muramyl peptides. J. Immunother. Emphasis. Tumor Immunol. 13 (1993), 252–260.
51. Honda, T., Inagawa, H., Yamamoto, I., Expression of chemotaxis- and angiogenesis-related factors in human monocytes following interaction with colon cancer cells is suppressed by low-dose lipopolysaccharide. Anticancer Res. 34 (2014), 4609–4613.
52. International agency for research on cancer, W.H.O. 2015. Globocan 2012: Estimated Incidence Mortality and Prevalence Worldwide of Colorectal Cancer in 2012. In: International agency for research on cancer, World Health Organisation.
53. Itzkowitz, S.H., Harpaz, N., Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126 (2004), 1634–1648.
54. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J. Clin. 61 (2011), 69–90.
55. Karpoff, H.M., Tung, C., Ng, B., Fong, Y., Interferon gamma protects against hepatic tumor growth in rats by increasing Kupffer cell tumoricidal activity. Hepatology 24 (1996), 374–379.
56. Khorana, A.A., Ryan, C.K., Cox, C., Eberly, S., Sahasrabudhe, D.M., Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer 97 (2003), 960–968.
57. Kleinerman, E.S., Jia, S.F., Griffin, J., Seibel, N.L., Benjamin, R.S., Jaffe, N., Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J. Clin. Oncol. 10 (1992), 1310–1316.
58. Klug, F., Prakash, H., Huber, P.E., Seibel, T., Bender, N., Halama, N., Pfirschke, C., Voss, R.H., Timke, C., Umansky, L., Klapproth, K., Schakel, K., Garbi, N., Jager, D., Weitz, J., Schmitz-Winnenthal, H., Hammerling, G.J., Beckhove, P., Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24 (2013), 589–602.
59. Koide, N., Nishio, A., Sato, T., Sugiyama, A., Miyagawa, S., Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am. J. Gastroenterol. 99 (2004), 1667–1674.
60. Kovalcsik, E., Lowe, K., Fischer, M., Dalgleish, A., Bodman-Smith, M.D., Poly(I:C)-induced tumour cell death leads to DC maturation and Th1 activation. Cancer Immunol. Immunother. 60 (2011), 1609–1624.
61. Lackner, C., Jukic, Z., Tsybrovskyy, O., Jatzko, G., Wette, V., Hoefler, G., Klimpfinger, M., Denk, H., Zatloukal, K., Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch. 445 (2004), 160–167.
62. Lamm, D.L., Blumenstein, B.A., Crawford, E.D., Montie, J.E., Scardino, P., Grossman, H.B., Stanisic, T.H., Smith, J.A. Jr., Sullivan, J., Sarosdy, M.F., Chrissman, J.D., Coltman, C.A., A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N. Engl. J. Med. 325 (1991), 1205–1209.
63. Laoui, D., Van Overmeire, E., Di Conza, G., Aldeni, C., Keirsse, J., Morias, Y., Movahedi, K., Houbracken, I., Schouppe, E., Elkrim, Y., Karroum, O., Jordan, B., Carmeliet, P., Gysemans, C., De, B.P., Mazzone, M., Van Ginderachter, J.A., Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res. 74 (2014), 24–30.
64. Lee, A.H., Happerfield, L.C., Bobrow, L.G., Millis, R.R., Angiogenesis and inflammation in invasive carcinoma of the breast. J. Clin. Pathol. 50 (1997), 669–673.
65. Leek, R.D., Lewis, C.E., Whitehouse, R., Greenall, M., Clarke, J., Harris, A.L., Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56 (1996), 4625–4629.
66. Li, T.T., Ogino, S., Qian, Z.R., Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy. World J. Gastroenterol. 20 (2014), 17699–17708.
67. Lin, E.Y., Nguyen, A.V., Russell, R.G., Pollard, J.W., Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193 (2001), 727–740.
68. Lin, E.Y., Pollard, J.W., Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 67 (2007), 5064–5066.
69. Locati, M., Mantovani, A., Sica, A., Macrophage activation and polarization as an adaptive component of innate immunity. Adv. Immunol. 120 (2013), 163–184.
70. Lodillinsky, C., Langle, Y., Guionet, A., Gongora, A., Baldi, A., Sandes, E.O., Casabe, A., Eijan, A.M., Bacillus calmette guerin induces fibroblast activation both directly and through macrophages in a mouse bladder cancer model. PLoS One, 5, 2010, e13571.
71. Luo, Y., Knudson, M.J., Mycobacterium bovis bacillus Calmette-Guerin-induced macrophage cytotoxicity against bladder cancer cells. Clin. Dev. Immunol., 2010, 357591.
72. Makitie, T., Summanen, P., Tarkkanen, A., Kivela, T., Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 42 (2001), 1414–1421.
73. Mantovani, A., Allavena, P., The interaction of anticancer therapies with tumor-associated macrophages. J. Exp. Med., 2015.
74. Mariani, F., Sena, P., Roncucci, L., Inflammatory pathways in the early steps of colorectal cancer development. World J. Gastroenterol. 20 (2014), 9716–9731.
75. Martinez, F.O., Gordon, S., Locati, M., Mantovani, A., Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 177 (2006), 7303–7311.
76. Martinez, F.O., Sica, A., Mantovani, A., Locati, M., Macrophage activation and polarization. Front. Biosci. 13 (2008), 453–461.
77. McDougall, S.R., Anderson, A.R., Chaplain, M.A., Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. J. Theor. Biol. 241 (2006), 564–589.
78. Meyers, P.A., Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev. Anticancer Ther. 9 (2009), 1035–1049.
79. Mills, C.D., Kincaid, K., Alt, J.M., Heilman, M.J., Hill, A.M., M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 164 (2000), 6166–6173.
80. Minard-Colin, V., Xiu, Y., Poe, J.C., Horikawa, M., Magro, C.M., Hamaguchi, Y., Haas, K.M., Tedder, T.F., Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 112 (2008), 1205–1213.
81. Montalvao, F., Garcia, Z., Celli, S., Breart, B., Deguine, J., van Rooijen, N., Bousso, P., The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J. Clin. Invest. 123 (2013), 5098–5103.
82. Mosolits, S., Nilsson, B., Mellstedt, H., Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert. Rev. Vaccines 4 (2005), 329–350.
83. Mosser, D.M., Edwards, J.P., Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8 (2008), 958–969.
84. Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., Van Ginderachter, J.A., Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111 (2008), 4233–4244.
85. Murray, P.J., Allen, J.E., Biswas, S.K., Fisher, E.A., Gilroy, D.W., Goerdt, S., Gordon, S., Hamilton, J.A., Ivashkiv, L.B., Lawrence, T., Locati, M., Mantovani, A., Martinez, F.O., Mege, J.L., Mosser, D.M., Natoli, G., Saeij, J.P., Schultze, J.L., Shirey, K.A., Sica, A., Suttles, J., Udalova, I., Van, G., inderachter, J.A., Vogel, S.N., Wynn, T.A., Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41 (2014), 14–20.
86. Nagorsen, D., Voigt, S., Berg, E., Stein, H., Thiel, E., Loddenkemper, C., Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J. Transl. Med., 5, 2007, 62.
87. Nebiker, C.A., Han, J., Eppenberger-Castori, S., Iezzi, G., Hirt, C., Amicarella, F., Cremonesi, E., Huber, X., Padovan, E., Angrisani, B., Droeser, R.A., Rosso, R., Bolli, M., Oertli, D., von, H.U., Adamina, M., Muraro, M.G., Mengus, C., Zajac, P., Sconocchia, G., Zuber, M., Tornillo, L., Terracciano, L., Spagnoli, G.C., GM-CSF production by tumor cells is associated with improved survival in colorectal cancer. Clin. Cancer Res. 20 (2014), 3094–3106.
88. Ohno, S., Ohno, Y., Suzuki, N., Kamei, T., Koike, K., Inagawa, H., Kohchi, C., Soma, G., Inoue, M., Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res. 24 (2004), 3335–3342.
89. Oosterling, S.J., van der Bij, G.J., Meijer, G.A., Tuk, C.W., van Garderen, E., van Rooijen, N., Meijer, S., van der Sijp, J.R., Beelen, R.H., van Egmond, M., Macrophages direct tumour histology and clinical outcome in a colon cancer model. J. Pathol. 207 (2005), 147–155.
90. Otten, M.A., van der Bij, G.J., Verbeek, S.J., Nimmerjahn, F., Ravetch, J.V., Beelen, R.H., van de Winkel, J.G., van Egmond, M., Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J. Immunol. 181 (2008), 6829–6836.
91. Otto, F., Schmid, P., Mackensen, A., Wehr, U., Seiz, A., Braun, M., Galanos, C., Mertelsmann, R., Engelhardt, R., Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur. J. Cancer 32A (1996), 1712–1718.
92. Papetti, M., Herman, I.M., Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol. Cell Physiol. 282 (2002), C947–C970.
93. Pastorino, S., Carta, L., Puppo, M., Melillo, G., Bosco, M.C., Varesio, L., Picolinic acid- or desferrioxamine-inducible autocrine activation of macrophages engineered to produce IFNgamma: an approach for gene therapy. Gene Ther. 11 (2004), 560–568.
94. Phillips, N.C., Tsao, M.S., Liposomal muramyl dipeptide therapy of experimental M5076 liver metastases in mice. Cancer Immunol. Immunother. 33 (1991), 85–90.
95. Popivanova, B.K., Kostadinova, F.I., Furuichi, K., Shamekh, M.M., Kondo, T., Wada, T., Egashira, K., Mukaida, N., Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res. 69 (2009), 7884–7892.
96. Propper, D.J., Chao, D., Braybrooke, J.P., Bahl, P., Thavasu, P., Balkwill, F., Turley, H., Dobbs, N., Gatter, K., Talbot, D.C., Harris, A.L., Ganesan, T.S., Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clin. Cancer Res. 9 (2003), 84–92.
97. Pyonteck, S.M., Akkari, L., Schuhmacher, A.J., Bowman, R.L., Sevenich, L., Quail, D.F., Olson, O.C., Quick, M.L., Huse, J.T., Teijeiro, V., Setty, M., Leslie, C.S., Oei, Y., Pedraza, A., Zhang, J., Brennan, C.W., Sutton, J.C., Holland, E.C., Daniel, D., Joyce, J.A., CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19 (2013), 1264–1272.
98. Rahbari, N.N., Aigner, M., Thorlund, K., Mollberg, N., Motschall, E., Jensen, K., Diener, M.K., Buchler, M.W., Koch, M., Weitz, J., Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 138 (2010), 1714–1726.e13.
99. Remels, L., Fransen, L., Huygen, K., De Baetselier, P., Poly I:C activated macrophages are tumoricidal for TNF-alpha-resistant 3LL tumor cells. J. Immunol. 144 (1990), 4477–4486.
100. Richter, C., Gogvadze, V., Schlapbach, R., Schweizer, M., Schlegel, J., Nitric oxide kills hepatocytes by mobilizing mitochondrial calcium. Biochem. Biophys. Res. Commun. 205 (1994), 1143–1150.
101. Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M.L., Segura, I., Li, X., Knevels, E., Costa, S., Vinckier, S., Dresselaer, T., Akerud, P., De, M., ol, M., Salomaki, H., Phillipson, M., Wyns, S., Larsson, E., Buysschaert, I., Botling, J., Himmelreich, U., Van, G., inderachter, J.A., De, P., alma, M., Dewerchin, M., Claesson-Welsh, L., Carmeliet, P., HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19 (2011), 31–44.
102. Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C.M., Pryer, N., Daniel, D., Hwang, E.S., Rugo, H.S., Coussens, L.M., Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26 (2014), 623–637.
103. Rushfeldt, C., Sveinbjornsson, B., Seljelid, R., Smedsrod, B., Early events of hepatic metastasis formation in mice: role of Kupffer and NK-cells in natural and interferon-gamma-stimulated defense. J. Surg. Res. 82 (1999), 209–215.
104. Salvesen, H.B., Akslen, L.A., Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int. J. Cancer 84 (1999), 538–543.
105. Schuurman, B., Heuff, G., Beelen, R.H., Meyer, S., Enhanced human Kupffer cell-mediated cytotoxicity after activation of the effector cells and modulation of the target cells by interferon-gamma: a mechanistic study at the cellular level. Cell Immunol. 165 (1995), 141–147.
106. Shabo, I., Olsson, H., Elkarim, R., Sun, X.F., Svanvik, J., Macrophage Infiltration in tumor stroma is related to tumor cell expression of CD163 in colorectal cancer. Cancer Microenviron. 7 (2014), 61–69.
107. Siveen, K.S., Kuttan, G., Role of macrophages in tumour progression. Immunol. Lett. 123 (2009), 97–102.
108. Steidl, C., Lee, T., Shah, S.P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S.J., Iqbal, J., Weisenburger, D.D., Bast, M.A., Rosenwald, A., Muller-Hermelink, H.K., Rimsza, L.M., Campo, E., Delabie, J., Braziel, R.M., Cook, J.R., Tubbs, R.R., Jaffe, E.S., Lenz, G., Connors, J.M., Staudt, L.M., Chan, W.C., Gascoyne, R.D., Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Engl. J. Med. 362 (2010), 875–885.
109. Stout, R.D., Jiang, C., Matta, B., Tietzel, I., Watkins, S.K., Suttles, J., Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J. Immunol. 175 (2005), 342–349.
110. Su, X., Yu, Y., Zhong, Y., Giannopoulou, E.G., Hu, X., Liu, H., Cross, J.R., Ratsch, G., Rice, C.M., Ivashkiv, L.B., Interferon-gamma regulates cellular metabolism and mRNA translation to potentiate macrophage activation. Nat. Immunol. 16 (2015), 838–849.
111. Su, Z., Yang, R., Zhang, W., Xu, L., Zhong, Y., Yin, Y., Cen, J., DeWitt, J.P., Wei, Q., The synergistic interaction between the calcineurin B subunit and IFN-gamma enhances macrophage antitumor activity. Cell Death Dis., 6, 2015, e1740.
112. Tazzyman, S., Lewis, C.E., Murdoch, C., Neutrophils: key mediators of tumour angiogenesis. Int. J. Exp. Pathol. 90 (2009), 222–231.
113. Torisu, H., Ono, M., Kiryu, H., Furue, M., Ohmoto, Y., Nakayama, J., Nishioka, Y., Sone, S., Kuwano, M., Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int. J. Cancer 85 (2000), 182–188.
114. Vacca, A., Ribatti, D., Ruco, L., Giacchetta, F., Nico, B., Quondamatteo, F., Ria, R., Iurlaro, M., Dammacco, F., Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br. J. Cancer 79 (1999), 965–970.
115. Vacchelli, E., Eggermont, A., Sautes-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., Galluzzi, L., Trial watch: toll-like receptor agonists for cancer therapy. Oncoimmunology, 2, 2013, e25238.
116. van der Bij, G.J., Bögels, M., Oosterling, S.J., Kroon, J., Schuckmann, D.T., de Vries, H.E., Meijer, S., Beelen, R.H., van Egmond, M., Tumor infiltrating macrophages reduce development of peritoneal colorectal carcinoma metastases. Cancer Lett. 262 (2008), 77–86.
117. van der Bij, G.J., Bögels, M., Otten, M.A., Oosterling, S.J., Kuppen, P.J., Meijer, S., Beelen, R.H., van Egmond, M., Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy. J. Hepatol. 53 (2010), 677–685.
118. van der Bij, G.J., Oosterling, S.J., Bögels, M., Bhoelan, F., Fluitsma, D.M., Beelen, R.H., Meijer, S., van Egmond, M., Blocking alpha2 integrins on rat CC531s colon carcinoma cells prevents operation-induced augmentation of liver metastases outgrowth. Hepatology 47 (2008), 532–543.
119. van der Bij, G.J., Oosterling, S.J., Meijer, S., Beelen, R.H., van Egmond, M., Therapeutic potential of Kupffer cells in prevention of liver metastases outgrowth. Immunobiology 210 (2005), 259–265.
120. van Netten, J.P., Ashmead, B.J., Parker, R.L., Thornton, I.G., Fletcher, C., Cavers, D., Coy, P., Brigden, M.L., Macrophage-tumor cell associations: a factor in metastasis of breast cancer?. J. Leukoc. Biol. 54 (1993), 360–362.
121. Vogelpoel, L.T., Hansen, I.S., Rispens, T., Muller, F.J., van, C., apel, T.M., Turina, M.C., Vos, J.B., Baeten, D.L., Kapsenberg, M.L., de, J., ong, E.C., den, D., unnen, J., Fc gamma receptor-TLR cross-talk elicits pro-inflammatory cytokine production by human M2 macrophages. Nat. Commun., 5, 2014, 5444.
122. Wang, W., Li, X., Zheng, D., Zhang, D., Peng, X., Zhang, X., Ai, F., Wang, X., Ma, J., Xiong, W., Li, G., Zhou, Y., Shen, S., Dynamic changes and functions of macrophages and M1/M2 subpopulations during ulcerative colitis-associated carcinogenesis in an AOM/DSS mouse model. Mol. Med. Rep. 11 (2015), 2397–2406.
123. Weiskopf, K., Weissman, I.L., Macrophages are critical effectors of antibody therapies for cancer. MAbs 7 (2015), 303–310.
124. Wiesenfeld, M., O'Connell, M.J., Wieand, H.S., Gonchoroff, N.J., Donohue, J.H., Fitzgibbons, R.J. Jr., Krook, J.E., Mailliard, J.A., Gerstner, J.B., Pazdur, R., Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. J. Clin. Oncol. 13 (1995), 2324–2329.
125. Wind, J., Tuynman, J.B., Tibbe, A.G., Swennenhuis, J.F., Richel, D.J., van, B., erge, H., enegouwen, M.I., Bemelman, W.A., Circulating tumour cells during laparoscopic and open surgery for primary colonic cancer in portal and peripheral blood. Eur. J. Surg. Oncol. 35 (2009), 942–950.
126. Wyckoff, J.B., Wang, Y., Lin, E.Y., Li, J.F., Goswami, S., Stanley, E.R., Segall, J.E., Pollard, J.W., Condeelis, J., Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 67 (2007), 2649–2656.
127. Youn, J.I., Nagaraj, S., Collazo, M., Gabrilovich, D.I., Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181 (2008), 5791–5802.
128. Zheng, L., Edil, B.H., Soares, K.C., El-Shami, K., Uram, J.N., Judkins, C., Zhang, Z., Onners, B., Laheru, D., Pardoll, D., Jaffee, E.M., Schulick, R.D., A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer. Ann. Surg. Oncol. 21 (2014), 3931–3937.
129. Zhou, Q., Peng, R.Q., Wu, X.J., Xia, Q., Hou, J.H., Ding, Y., Zhou, Q.M., Zhang, X., Pang, Z.Z., Wan, D.S., Zeng, Y.X., Zhang, X.S., The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J. Transl. Med., 8, 2010, 13.